What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Treatment with SHR-A2102 in combination with fixed dose Adebrelimab.”In the company’s words, NCT06879145 on ClinicalTrials.gov
- Tested for
- Advanced Solid Tumors (3 trials), Advanced Urothelial Carcinoma (2 trials), Recurrent Cervical Cancer, Metastatic Cervical Cancer, Muscular Invasive Bladder Cancer (MIBC), Non-small Cell Lung Cancer, Advanced Malignant Tumour, Advanced or Metastatic Non-small Cell Lung Cancer and 2 more
- Main trialPhase 3
- “To evaluate the efficacy and safety of SHR-A2102 for injection versus Investigator-selected Therapy in patients with Locally advanced or Metastatic Urothelial Carcinoma who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.”In the company’s words, NCT06738251 on ClinicalTrials.gov
Other drugs for Advanced Solid Tumors
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up8
- DecPhase 2 trial completes · ClinicalTrials.gov
- Mar 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Apr 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 May 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2028Phase 2 trial completes · ClinicalTrials.gov
- Dec 2031Phase 2/3 trial completes · ClinicalTrials.gov
- 31 Dec 2031Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials15
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jul 2026 | A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma | |
| Phase 3Recruiting | Dec 2027 | A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer | |
| Phase 2/3Recruiting | Dec 2031 | Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316) | |
| Phase 2Recruiting | Oct 2026 | A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer | |
| Phase 2Recruiting | Dec 2026 | A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour | |
| Phase 2Recruiting | Dec 2028 | A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors | |
| Phase 1/2Recruiting | Oct 2026 | A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer | |
| Phase 1/2Recruiting | Mar 2027 | A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer | |
| Phase 1/2Recruiting | 31 May 2027 | A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma | |
| Phase 1/2Recruiting | 31 Dec 2031 | A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors | |
| Phase 1Recruiting | 31 Aug 2025 | Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors | |
| Phase 1Not yet recruiting | 30 Apr 2027 | A Phase Ib Study of HS-10504 Combined Therapy in NSCLC | |
| Phase 2Unknown | 31 Aug 2025 | A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy | |
| Phase 1/2Unknown | 30 Apr 2026 | A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | |
| Phase 1Unknown | 31 Aug 2025 | A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026